Trials / Active Not Recruiting
Active Not RecruitingNCT07069569
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
A Randomized, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Combination With Hepatitis B Vaccine or Pegylated Interferon α-2b (Peg-IFN) in Participants With HBeAg-Negative Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogue (NAs)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Ausper Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AHB-137 | AHB-137 will be injected. |
| DRUG | Peg-IFN | Peg-IFN will be administered . |
| DRUG | Hepatitis B Vaccine | Hepatitis B vaccine will be administered. |
Timeline
- Start date
- 2025-05-30
- Primary completion
- 2027-01-01
- Completion
- 2027-05-01
- First posted
- 2025-07-16
- Last updated
- 2025-11-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07069569. Inclusion in this directory is not an endorsement.